In particular, combined treatment of TST and anti‐4‐1BB antibody in LLC‐1 syngeneic tumor model induced synergistic therapeutic outcome against immune‐resistant lung tumors as well as 2.72‐folds increase in the CD3+ T cells in tumor tissues compared with that in the anti‐4‐1BB antibody treatment group. This evidence concerns the gene TNFRSF9 and neoplasm.